Artificial intelligence is increasingly becoming a cornerstone of drug discovery, and VERAXA Biotech AG (NASDAQ: VRXA) is positioning itself at the forefront of this trend. The company's collaboration with Ardigen, a research organization specializing in AI, computational biology, and bioinformatics, is set to enhance VERAXA's oncology pipeline by leveraging AI to identify optimal dual-target combinations for its proprietary BiTAC platform and antibody-drug conjugates (ADCs).
VERAXA's innovative "AND-gated" approach is particularly suited to AI-driven analysis. This method activates therapies only when two cancer-associated targets are present on the same cell, which could improve precision and reduce off-target effects. By integrating AI into target validation, the companies aim to reduce development risks and accelerate the path to clinical trials.
The partnership also opens the door to revisiting historical clinical and preclinical data. AI can analyze complex genomic, proteomic, and clinical datasets to identify safer applications for targets or therapies that were previously abandoned due to toxicity concerns. This could breathe new life into promising drug candidates that were shelved, potentially expanding the therapeutic arsenal against cancer.
For more details, the full article is available at https://ibn.fm/2U2hQ.
VERAXA Biotech is dedicated to building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs. The company's pipeline is rapidly advancing, guided by rigorous quality-by-design principles and founded on scientific breakthroughs from the European Molecular Biology Laboratory.
The integration of AI into VERAXA's R&D strategy underscores a broader industry shift toward data-driven approaches in oncology. As AI continues to evolve, its role in drug discovery is expected to expand, offering new ways to tackle complex diseases like cancer. For VERAXA, this collaboration could be a key differentiator in a competitive landscape.
Investors and stakeholders can follow the latest news and updates on VERAXA Biotech in the company's newsroom at https://ibn.fm/VRXA.
